Abiopharma

New Form 4 - IOVANCE BIOTHERAPEUTICS, INC. Filed: 2025-08-08 AccNo: 0001104659-25-075687 Size: 8 KB

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

New Form 425 - CureVac N.V. Filed: 2025-08-08 AccNo: 0001193125-25-176985 Size: 21 KB

New Form SCHEDULE 13G - Cellectar Biosciences, Inc. Filed: 2025-08-08 AccNo: 0001753926-25-001260 Size: 17 KB

New Form 424B4 - Aptevo Therapeutics Inc. Filed: 2025-08-08 AccNo: 0000950170-25-105823 Size: 401 KB

New Form 4 - Vericel Corp Filed: 2025-08-08 AccNo: 0001140361-25-029856 Size: 8 KB

New Form 3 - IOVANCE BIOTHERAPEUTICS, INC. Filed: 2025-08-08 AccNo: 0001104659-25-075679 Size: 3 KB

New Form DEFA14A - XWELL, Inc. Filed: 2025-08-08 AccNo: 0001104659-25-075678 Size: 24 KB

New Form 4 - Vanda Pharmaceuticals Inc. Filed: 2025-08-08 AccNo: 0000950170-25-105819 Size: 4 KB

- Femasys Announces Second Quarter Financial Results for 2025

Evolus - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Amwell makes grant to new employees under inducement plan

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates